IL297658A - Pharmaceutical preparation for drug administration - Google Patents

Pharmaceutical preparation for drug administration

Info

Publication number
IL297658A
IL297658A IL297658A IL29765822A IL297658A IL 297658 A IL297658 A IL 297658A IL 297658 A IL297658 A IL 297658A IL 29765822 A IL29765822 A IL 29765822A IL 297658 A IL297658 A IL 297658A
Authority
IL
Israel
Prior art keywords
composition
active ingredient
compositions
condition
pct
Prior art date
Application number
IL297658A
Other languages
English (en)
Hebrew (he)
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2007306.0A external-priority patent/GB202007306D0/en
Priority claimed from GBGB2009905.7A external-priority patent/GB202009905D0/en
Priority claimed from GBGB2018901.5A external-priority patent/GB202018901D0/en
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of IL297658A publication Critical patent/IL297658A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL297658A 2020-05-18 2021-05-18 Pharmaceutical preparation for drug administration IL297658A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2007306.0A GB202007306D0 (en) 2020-05-18 2020-05-18 New pharmaceutical composition
GBGB2009905.7A GB202009905D0 (en) 2020-06-29 2020-06-29 New pharmaceutical composition
GBGB2018901.5A GB202018901D0 (en) 2020-12-01 2020-12-01 New pharmaceutical composition
PCT/GB2021/051191 WO2021234366A1 (en) 2020-05-18 2021-05-18 New pharmaceutical composition for drug delivery

Publications (1)

Publication Number Publication Date
IL297658A true IL297658A (en) 2022-12-01

Family

ID=76138084

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297658A IL297658A (en) 2020-05-18 2021-05-18 Pharmaceutical preparation for drug administration

Country Status (25)

Country Link
US (2) US11737980B2 (https=)
EP (2) EP3962455B1 (https=)
JP (1) JP2023526098A (https=)
KR (1) KR20230012502A (https=)
CN (2) CN121265577A (https=)
AU (1) AU2021276611A1 (https=)
BR (1) BR112022023307A2 (https=)
CA (1) CA3178769A1 (https=)
CL (1) CL2022002979A1 (https=)
CO (1) CO2022015183A2 (https=)
DK (1) DK3962455T3 (https=)
ES (1) ES2929818T3 (https=)
HR (1) HRP20221361T1 (https=)
HU (1) HUE060573T2 (https=)
IL (1) IL297658A (https=)
LT (1) LT3962455T (https=)
MD (1) MD3962455T2 (https=)
MX (1) MX2022014216A (https=)
PE (1) PE20230382A1 (https=)
PL (1) PL3962455T3 (https=)
PT (1) PT3962455T (https=)
RS (1) RS63725B1 (https=)
SI (1) SI3962455T1 (https=)
SM (1) SMT202200411T1 (https=)
WO (1) WO2021234366A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
RS63725B1 (sr) 2020-05-18 2022-12-30 Orexo Ab Nova farmaceutska kompozicija za davanje leka
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
AR127780A1 (es) * 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) * 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
AR127783A1 (es) * 2021-11-25 2024-02-28 Orexo Ab Composición farmacéutica que comprende compuestos de drogas biofarmacéuticas
CN119278026A (zh) 2022-03-31 2025-01-07 好利安科技有限公司 吸入复合材料和基于载体的制剂组合
WO2023209662A1 (en) * 2022-04-29 2023-11-02 Pentide Therapeutics Limited Pharmaceutical compositions of semaglutide and the methods of use thereof
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
WO2024031148A1 (en) * 2022-08-11 2024-02-15 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
GB202301322D0 (en) * 2023-01-30 2023-03-15 Therakind Ltd Antiemetic pharmaceutical compositions for nasal delivery
AU2024260882A1 (en) * 2023-04-24 2025-11-06 Cyrano Therapeutics, Inc. Treatment of memory loss with phosphodiesterase inhibitors
GB202308123D0 (en) * 2023-05-31 2023-07-12 Orexo Ab New copmosition
AU2024280073A1 (en) * 2023-05-31 2025-12-11 Orexo Ab Spray-dried compositions comprising adrenergic receptor modulators
EP4727536A1 (en) * 2023-06-14 2026-04-22 Genus Lifesciences Inc. Pharmaceutical oral solid dosage forms including phenobarbital and methods of making and using the same
US20260108686A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759520A (fr) 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
SE8904296D0 (sv) 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
EP0657176B1 (en) 1993-12-06 2000-09-20 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
DE69913113T2 (de) 1998-03-10 2004-08-26 Valois S.A.S. Behälter, verfahren zur befüllung dieses behälter und abgabevorrichtung für das im behälter enthaltene pulver
KR100606857B1 (ko) * 1998-07-08 2006-08-01 키린-암젠 인코포레이티드 고분자 의약품 함유 분말상 경점막 투여 제제
JP2000178184A (ja) 1998-12-17 2000-06-27 Lion Corp 粒状組成物、錠剤及び粒状組成物の製造方法
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
GB0003782D0 (en) 2000-02-17 2000-04-05 Dumex Ltd As Process
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
KR20010107754A (ko) 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
IN192750B (https=) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6443152B1 (en) 2001-01-12 2002-09-03 Becton Dickinson And Company Medicament respiratory delivery device
LU90825B1 (en) 2001-09-06 2003-03-07 Iee Sarl Method for the determination of one or more parameters of a seat passenger
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0201367D0 (en) 2002-01-22 2002-03-13 Ml Lab Plc Composition
AU2006207868A1 (en) 2002-03-20 2006-09-28 Alkermes, Inc. Method and apparatus for producing dry particles
WO2004002551A2 (en) 2002-06-28 2004-01-08 Advanced Inhalation Research, Inc. Inhalable epinephrine
WO2004054511A2 (en) 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
CN1777411B (zh) 2003-02-24 2013-01-02 药品生产公司 经粘膜药物递送系统
WO2004100857A2 (en) 2003-05-07 2004-11-25 Akina, Inc. Highly plastic granules for making fast melting tablets
US20060115529A1 (en) 2003-05-07 2006-06-01 Seonghoon Jeong Fast-melting tablets having taste-masking and sustained release properties
CA2528064C (en) * 2003-06-13 2010-01-12 Advanced Inhalation Research, Inc. Low dose pharmaceutical powders for inhalation
CN100471497C (zh) 2003-06-25 2009-03-25 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻粉剂
US20050042178A1 (en) 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
AU2003272959A1 (en) 2003-10-09 2005-04-27 Bioactis Limited Powdery medicine dispensing device for nasal cavity
WO2005044186A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
CN1640402A (zh) 2004-01-02 2005-07-20 广东奇方药业有限公司 一种稳定的纳洛酮粉针剂
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
CN1615867A (zh) 2004-10-22 2005-05-18 北京阳光润禾科技有限公司 注射用盐酸纳洛酮冻干粉针制剂
CN1781479B (zh) 2004-12-02 2010-06-30 和记黄埔医药企业有限公司 一种马蔺子素分散体系及其制备方法
CN101132769A (zh) 2005-02-10 2008-02-27 奥瑞克索股份公司 用于药物的跨黏膜给药的药物组合物
KR101233235B1 (ko) 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
US20070202163A1 (en) 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
CN1939358A (zh) 2005-09-30 2007-04-04 江西本草天工科技有限责任公司 肿节风分散片
CN1813739A (zh) 2005-11-25 2006-08-09 王颖 一种注射用盐酸纳美芬冻干粉针制剂
JP2009524646A (ja) 2006-01-27 2009-07-02 ザ・プロヴォスト，フェローズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホーリー・アンド・アンディヴァイデッド・トリニティー・オブ・クイーン・エリザベス，ニア・ダブリン 多孔性微粒子の製造方法
WO2007096906A2 (en) 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
US20100226979A1 (en) 2006-03-21 2010-09-09 Jubilant Organosys Limited Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate
US20090208576A1 (en) 2006-03-31 2009-08-20 Gandhi Anilkumar S Orally Disintegrating Tablets
EP2061427B1 (en) 2006-09-15 2011-07-20 Echo Pharmaceuticals B.V. Granulate containing a pharmaceutically active substance and an emulsifier and method for its manufacture
US20080269347A1 (en) 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
CA2678455C (en) 2007-01-10 2019-02-12 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
CA2718255C (en) 2008-03-11 2016-08-23 Aska Pharmaceutical Co., Ltd. Solid dispersion and pharmaceutical composition of the same, and production processes thereof
US20090246256A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
US20090264530A1 (en) 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
DK2432502T3 (en) * 2009-05-20 2018-03-12 Aeras STABLE, SPRAY DRIED, IMMUNOGENE, VIRUS COMPOSITIONS
MX337126B (es) * 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
CA2775404C (en) 2009-09-25 2017-01-03 Dr. Reddy's Laboratories Limited Formulations comprising triptan compounds
CA2809263A1 (en) 2010-08-27 2012-03-01 Eleni Dokou Pharmaceutical composition and administrations thereof
AU2011296343B2 (en) * 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
MY165826A (en) 2010-10-01 2018-05-17 Cipla Ltd Pharmaceutical composition
CA2819663C (en) 2010-12-02 2019-12-24 Adare Pharmaceuticals, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
MX359670B (es) 2011-02-18 2018-10-05 Biolingus Ip Llc Proceso para preparar productos que comprenden activos estabilizados y composiciones que los comprenden.
MY194947A (en) 2011-05-13 2022-12-27 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
JP6054380B2 (ja) 2012-05-11 2016-12-27 株式会社アクティバスファーマ 有機化合物ナノ粉体、その製造方法ならびに懸濁液
CA3169368A1 (en) * 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US9789071B2 (en) * 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2014004400A2 (en) 2012-06-28 2014-01-03 The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Nasal dry powder delivery system for vaccines and other treatment agents
FR3007992B1 (fr) 2013-07-05 2018-01-26 Aptar France Sas Dispositif de distribution de produit fluide ou pulverulent.
AU2014315459A1 (en) 2013-09-03 2016-04-07 G2B Pharma Inc. Intranasal formulation for the treatment of cardiopulmonary resuscitation (CPR), cardiac life support (CLS), anaphylaxis and/or anaphylactoid reactions
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
WO2015095389A1 (en) 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
DK3125875T3 (da) * 2014-04-04 2023-07-24 Ai Therapeutics Inc Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
US20190008759A1 (en) 2014-07-03 2019-01-10 Darren Rubin Safer and more effective methods of transmucosal delivery for raising blood pressure and stimulating the body
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3174534A1 (en) 2014-08-01 2017-06-07 KRKA, d.d., Novo mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
CA2961829C (en) 2014-09-18 2023-09-12 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
JP6919093B2 (ja) 2014-10-08 2021-08-18 ザンボン ソシエタ ペル アチオニ 配合物の安定性を高めるために噴霧乾燥によって得られる少なくとも１種の乾燥粉末を含む組成物
ES2949137T3 (es) 2014-11-14 2023-09-25 Asoltech Srl Composición a base de coq10 campo de la invención
EP3025705B8 (en) 2014-11-25 2018-11-28 Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi Stable ivabradine formulations
CN104547220A (zh) 2014-12-30 2015-04-29 陈宏� 一种治疗儿童视觉疲劳的中药组合物及其制剂
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
EA034820B1 (ru) 2015-02-17 2020-03-25 Эли Лилли Энд Компани Порошковый состав для интраназального введения для лечения гипогликемии
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
EP3280740A4 (en) 2015-04-08 2019-03-27 Ling, Chang-Chun PHARMACEUTICAL COMPOSITIONS OF POLYANIONIC AND NONIONIC CYCLODEXTRIN BASED DENDRIMERS AND USES THEREOF
KR20180002750A (ko) 2015-05-01 2018-01-08 키비타스 테라퓨틱스, 인코포레이티드. 폐 전달용 졸미트립탄 분말
US10039710B2 (en) 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
JP6953414B2 (ja) 2016-01-20 2021-10-27 フラリー パウダーズ エルエルシーＦｌｕｒｒｙ Ｐｏｗｄｅｒｓ，Ｌｌｃ 親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法
ITUB20161027A1 (it) * 2016-02-24 2017-08-24 Altergon Sa Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio
US20190364946A1 (en) 2016-03-16 2019-12-05 Omegatri As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
US20170312226A1 (en) 2016-04-28 2017-11-02 Ascent Pharmaceuticals, Inc. Pharmaceutical dosage forms
EP3463375A1 (en) 2016-06-03 2019-04-10 M Et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
US20190350881A1 (en) 2016-06-17 2019-11-21 Ys Pharmtech Stabilization of epinephrine formulations
RU2747237C2 (ru) 2016-07-06 2021-04-29 Маккормик Энд Компани, Инкорпорейтед Природные инкапсулированные ароматизирующие продукты
WO2018025089A2 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Pharmaceutical compositions
US20190231707A1 (en) 2016-09-28 2019-08-01 Chrono Therapeutics Inc. Transdermal drug delivery device for delivering opioids
WO2018064672A1 (en) 2016-09-30 2018-04-05 Opiant Pharmaceuticals, Inc. Treatment with intranasal naloxone
US20180092839A1 (en) 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
WO2018089709A1 (en) 2016-11-09 2018-05-17 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
CN110139651A (zh) 2016-11-18 2019-08-16 欧邦特制药公司 用于治疗阿片样物质过量的组合物和方法
WO2018148382A1 (en) 2017-02-10 2018-08-16 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery
WO2018195029A1 (en) 2017-04-17 2018-10-25 Insys Development Company, Inc. Epinephrine spray formulations
US11331270B2 (en) 2017-08-20 2022-05-17 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
US20180193332A1 (en) 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
WO2019139865A1 (en) 2018-01-10 2019-07-18 Insys Development Company. Inc. Methods of stabilizing epinephrine
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CN112512506A (zh) 2018-06-13 2021-03-16 希克玛药物美国股份有限公司 肾上腺素喷雾制剂
WO2020205663A1 (en) 2019-03-29 2020-10-08 The Regents Of The University Of California Inhaled statins as bronchodilators to improve lung function in respiratory diseases
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
US11400045B2 (en) 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
RS63725B1 (sr) 2020-05-18 2022-12-30 Orexo Ab Nova farmaceutska kompozicija za davanje leka
US11617716B2 (en) 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Also Published As

Publication number Publication date
ES2929818T3 (es) 2022-12-02
BR112022023307A2 (pt) 2022-12-20
PL3962455T3 (pl) 2023-01-16
RS63725B1 (sr) 2022-12-30
DK3962455T3 (en) 2022-10-24
JP2023526098A (ja) 2023-06-20
US12357573B2 (en) 2025-07-15
AU2021276611A1 (en) 2022-12-15
CN115666513A (zh) 2023-01-31
HUE060573T2 (hu) 2023-03-28
KR20230012502A (ko) 2023-01-26
CN115666513B (zh) 2025-09-30
EP3962455B1 (en) 2022-08-31
EP4154866A1 (en) 2023-03-29
WO2021234366A1 (en) 2021-11-25
HRP20221361T1 (hr) 2023-01-06
CO2022015183A2 (es) 2023-02-27
CN121265577A (zh) 2026-01-06
LT3962455T (lt) 2022-10-25
PT3962455T (pt) 2022-10-13
PE20230382A1 (es) 2023-03-06
SI3962455T1 (sl) 2022-11-30
US11737980B2 (en) 2023-08-29
MX2022014216A (es) 2022-12-07
US20220087938A1 (en) 2022-03-24
CA3178769A1 (en) 2021-11-25
CL2022002979A1 (es) 2023-05-12
US20240024244A1 (en) 2024-01-25
MD3962455T2 (ro) 2022-12-31
EP3962455A1 (en) 2022-03-09
SMT202200411T1 (it) 2022-11-18

Similar Documents

Publication Publication Date Title
US12357573B2 (en) Pharmaceutical composition for drug delivery
CN114096249B (zh) 用于鼻腔递送的药物组合物
US12268684B2 (en) Pharmaceutical composition for nasal delivery
KR20240103005A (ko) 아드레날린을 포함하는 약학적 조성물
KR20240111769A (ko) 비강내 투여에 사용되는 새로운 약학적 장치
HK40090558A (en) New pharmaceutical composition for drug delivery
BR122025022559A2 (pt) Composição farmacêutica para entrega de fármacos
TW202320738A (zh) 用於藥物遞送之新穎醫藥組合物
KR20260019501A (ko) Cgrp 수용체 길항제를 포함하는 분무 건조 조성물
WO2023094817A1 (en) Pharmaceutical composition comprising atropine
HK40071082B (en) New pharmaceutical composition for drug delivery
HK40071082A (en) New pharmaceutical composition for drug delivery
KR20260016535A (ko) 아드레날린 수용체 조절제를 포함하는 분무 건조 조성물